Logo

Incyte's Pemazyre (pemigatinib) Receives the US FDA's Approval as the Novel Treatment for Adults with Previously Treated- Unresectable LA or Metastatic Cholangiocarcinoma

Share this

Incyte's Pemazyre (pemigatinib) Receives the US FDA's Approval as the Novel Treatment for Adults with Previously Treated- Unresectable LA or Metastatic Cholangiocarcinoma

Shots:

  • The approval is based on P-II FIGHT-202 (NCT02924376) study which involves assessing of Pemazyre (13.5 mg- qd) in adults with previously treated- locally advanced or metastatic cholangiocarcinoma with documented FGFR2 fusion or rearrangement
  • The study has three cohorts: Cohort A (FGFR2 fusions or rearrangements)- Cohort B (other FGF/FGFR genetic alterations) or Cohort C (no FGF/FGFR genetic alterations and resulted in OR 36%- mDOR 9.1 mos.
  • Pemazyre is an oral inhibitor of FGFR isoforms 1- 2 and 3 and has also received the US FDA’s BT Designation and ODD to treat patients with previously treated advanced/metastatic or unresectable FGFR2 translocated cholangiocarcinoma and for cholangiocarcinoma respectively

Click here ­to­ read full press release/ article | Ref: Incyte | Image: Incyte


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions